
Advancing Science. Improving Connections.
Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.

Our Patients
Focusing on the unmet medical needs of patients with rare disorders and their families
Our Company
Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases
Latest News
Zynerba Pharmaceuticals Provides Regulatory Update on Zygelâ„¢ in Fragile X Syndrome
Read MoreZynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES)
Read MoreZynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy Society (AES)
Read More